세계의 펩티드 치료제 시장 보고서(2025년)

Peptide therapeutics involve using peptides as medicinal treatments. Peptides constitute a distinct group of pharmacological compounds positioned molecularly between proteins and small molecules. Natural peptides serve diverse roles such as hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infectives. Leveraging peptides as therapies allows for targeted cell interaction and modulation of cellular responses, offering a broad spectrum of treatment possibilities.

The primary classifications of peptide therapeutics include generic and branded variants. Branded peptide therapeutics are drugs marketed under the brand names of major pharmaceutical companies that hold the patent for these medications. Branded drugs tend to be more costly than their generic counterparts, as they maintain a distinct brand identity. Peptide therapeutics can be administered through various routes such as parenteral, mucosal, oral, and transdermal. They find applications in treating a wide range of medical conditions, including cancer, cardiovascular diseases, central nervous system disorders, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatology issues, respiratory disorders, and acromegaly.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The peptide therapeutics market research report is one of a series of new reports from The Business Research Company that provides peptide therapeutics market statistics, including peptide therapeutics industry global market size, regional shares, competitors with a peptide therapeutics market share, detailed peptide therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide therapeutics industry. This peptide therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide therapeutics market size has grown strongly in recent years. It will grow from $45.15 billion in 2024 to $49.21 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increasing incidence of chronic diseases, growing understanding of molecular biology, expanding applications in oncology.

The peptide therapeutics market size is expected to see rapid growth in the next few years. It will grow to $74.98 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to rising demand for personalized medicine, expanding use in immunotherapy, advancements in peptide delivery systems, emerging peptide targets in infectious diseases, increasing focus on rare diseases. Major trends in the forecast period include technological advancements in peptide synthesis, growing investment and funding, emphasis on peptide drug safety, market expansion in emerging economies, integration of artificial intelligence (AI).

The forecast of 11.1% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. biopharmaceutical companies by inflating prices of peptide-based therapeutics manufactured in Germany and Denmark, resulting in delayed treatment availability for endocrine and metabolic disorders and raising specialty drug costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The peptide therapeutics market is poised for growth, primarily fueled by the escalating prevalence of chronic diseases. Chronic diseases, characterized by their prolonged and often incurable nature, are on the rise, driven by factors such as increased tobacco product usage, suboptimal nutrition, physical inactivity, and excessive alcohol consumption. Despite being challenging to cure, chronic diseases can be managed and, in some cases, controlled. The utilization of peptide therapeutics plays a crucial role in both the prevention and treatment of certain chronic diseases. Notably, in January 2023, the National Library of Medicine, a US-based agency, reported a significant projection for the United States, indicating that the number of individuals aged 50 and older with at least one chronic condition is expected to surge by 99.5%, reaching 142.66 million by the year 2050. As a result, the anticipated increase in the prevalence of chronic diseases is set to be a key driver for the growth of the peptide therapeutics market throughout the forecast period.

The growth trajectory of the peptide therapeutics market is expected to be significantly influenced by the increasing size of the geriatric population. Defined as individuals aged 65 years and older, the geriatric population faces a higher prevalence of various health conditions. Peptide therapeutics play a pivotal role in managing and treating these conditions by targeting specific pathways associated with age-related diseases, improving bone density, and mitigating the risk of fractures. Notably, global demographic trends, as highlighted by the World Health Organization in October 2022, indicate that 1 in 6 people will be 60 years or older by 2030, with a projected doubling of this age group to 2.1 billion individuals by 2050. Further emphasizing the impact on specific regions, the UK Parliament's House of Commons Library reported in June 2021 that the senior population in the United Kingdom is expected to increase, constituting 24% of the total population (17.4 million people) by the year 2043. This demographic shift underscores the growing importance of peptide therapeutics in addressing the healthcare needs of the elderly. As a result, the rise in the geriatric population emerges as a significant driver propelling the growth of the peptide therapeutics market in the foreseeable future.

Major companies in the peptide therapeutics market are actively focused on introducing advanced solutions to gain a competitive edge, with a notable emphasis on innovations such as the cell culture process. The cell culture process involves growing cells outside of their natural environment under controlled conditions, which includes isolating cells of interest from living tissue and maintaining them. As an illustrative example, in June 2023, Evonik Industries AG, a German-based specialty chemicals company, launched cQrex KC. Positioned as a next-generation peptide for biopharma applications, cQrex KC is specifically designed for the cell culture process used in the manufacturing of biological drugs. It empowers cell culture process developers to optimize cystine supply and enhance cell culture productivity. Notably, cQrex KC contributes to the development of vaccines, viral vectors, and cell therapies, showcasing a commitment to advancing technologies that support crucial aspects of biopharmaceutical production.

Major companies in the peptide therapeutic market are strategically focused on introducing advanced solutions, with a particular emphasis on innovations such as peptide drug discovery, aiming to gain a competitive edge. Peptide drug discovery involves the process of identifying, designing, and developing therapeutic agents composed of short chains of amino acids, known as peptides. A case in point is Fujitsu Limited, a Japan-based information and communications technology equipment and services company, which, in May 2023, unveiled the Biodrug Design Accelerator. This platform is specifically designed to support peptide drug discovery scientists in pharmaceutical companies throughout the design, make, test, analyze (DMTA) cycles. Operating as a web-based solution, the Biodrug Design Accelerator provides assistance to peptide designers by offering visualization of amino acid sequences. This strategic move reflects a commitment to leveraging advanced technologies to enhance and streamline the peptide drug discovery process, ultimately contributing to advancements in therapeutic solutions.

In July 2024, AstraZeneca plc, a pharmaceutical and biotechnology company based in England, acquired Amolyt Pharma for $1.05 billion. This acquisition supports AstraZeneca's larger strategy to enhance its capabilities in rare diseases and broaden its therapeutic offerings in areas of high demand. Amolyt Pharma is a clinical-stage biotechnology company located in France, focusing on the development of therapeutic peptides designed to treat rare endocrine and metabolic disorders.

Major companies operating in the peptide therapeutics market include Pfizer Inc., Jhonson & Jhonson, Abbvie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi SA, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk AS, Teva Pharmaceuticals Industries Ltd., Bachem Holding AG, PolyPeptide Laboratories BV, Arcus Biosciences Inc., Pepscan Therapeutics, Peptech Inc., Peptide Logic Inc., SELLAS Life Sciences Group, Ever Neuro Pharma GmbH, Zealand Pharma AG, PepGen Inc., Pepticom S.A., Peptide Technologies Corporation, SynPeptide Inc., Peptimmune Inc., Merck & Co Inc.

North America was the largest region in the peptide therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peptide therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide therapeutics market includes revenues earned by entities by creating drugs to treat a variety of diseases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peptide therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peptide therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Generic; Branded
• 2) By Route of Administration: Parenteral; Mucosal; Oral; Transdermal
• 3) By Application: Cancer; Cardiovascular Diseases; Central Nervous Systems; Metabolic Disorders; Infections; Hematological Disorders; Gastrointestinal Disorders; Dermatology; Respiratory Disorders; Acromegaly; Other Applications
• Subsegments:
• 1) By Generic: Generic Peptide Drugs; Biosimilars
• 2) By Branded: Innovative Peptide Drugs; Patent-Protected Peptides
• Companies Mentioned: Pfizer Inc.; Jhonson & Jhonson; Abbvie Inc.; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca plc; Sanofi SA; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Amgen Inc.; Novo Nordisk AS; Teva Pharmaceuticals Industries Ltd.; Bachem Holding AG; PolyPeptide Laboratories BV; Arcus Biosciences Inc.; Pepscan Therapeutics; Peptech Inc.; Peptide Logic Inc.; SELLAS Life Sciences Group; Ever Neuro Pharma GmbH; Zealand Pharma AG; PepGen Inc.; Pepticom S.A.; Peptide Technologies Corporation; SynPeptide Inc.; Peptimmune Inc.; Merck & Co Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Peptide Therapeutics Market Characteristics

3. Peptide Therapeutics Market Trends And Strategies

4. Peptide Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Peptide Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Peptide Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Peptide Therapeutics Market Growth Rate Analysis
• 5.4. Global Peptide Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Peptide Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Peptide Therapeutics Total Addressable Market (TAM)

6. Peptide Therapeutics Market Segmentation

• 6.1. Global Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic
• Branded
• 6.2. Global Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parenteral
• Mucosal
• Oral
• Transdermal
• 6.3. Global Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Cardiovascular Diseases
• Central Nervous Systems
• Metabolic Disorders
• Infections
• Hematological Disorders
• Gastrointestinal Disorders
• Dermatology
• Respiratory Disorders
• 6.4. Global Peptide Therapeutics Market, Sub-Segmentation Of Generic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Peptide Drugs
• Biosimilars
• 6.5. Global Peptide Therapeutics Market, Sub-Segmentation Of Branded, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Innovative Peptide Drugs
• Patent-Protected Peptides

7. Peptide Therapeutics Market Regional And Country Analysis

• 7.1. Global Peptide Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Peptide Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Peptide Therapeutics Market

• 8.1. Asia-Pacific Peptide Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Peptide Therapeutics Market

• 9.1. China Peptide Therapeutics Market Overview
• 9.2. China Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Peptide Therapeutics Market

• 10.1. India Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Peptide Therapeutics Market

• 11.1. Japan Peptide Therapeutics Market Overview
• 11.2. Japan Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Peptide Therapeutics Market

• 12.1. Australia Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Peptide Therapeutics Market

• 13.1. Indonesia Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Peptide Therapeutics Market

• 14.1. South Korea Peptide Therapeutics Market Overview
• 14.2. South Korea Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Peptide Therapeutics Market

• 15.1. Western Europe Peptide Therapeutics Market Overview
• 15.2. Western Europe Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Peptide Therapeutics Market

• 16.1. UK Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Peptide Therapeutics Market

• 17.1. Germany Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Peptide Therapeutics Market

• 18.1. France Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Peptide Therapeutics Market

• 19.1. Italy Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Peptide Therapeutics Market

• 20.1. Spain Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Peptide Therapeutics Market

• 21.1. Eastern Europe Peptide Therapeutics Market Overview
• 21.2. Eastern Europe Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Peptide Therapeutics Market

• 22.1. Russia Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Peptide Therapeutics Market

• 23.1. North America Peptide Therapeutics Market Overview
• 23.2. North America Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Peptide Therapeutics Market

• 24.1. USA Peptide Therapeutics Market Overview
• 24.2. USA Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Peptide Therapeutics Market

• 25.1. Canada Peptide Therapeutics Market Overview
• 25.2. Canada Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Peptide Therapeutics Market

• 26.1. South America Peptide Therapeutics Market Overview
• 26.2. South America Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Peptide Therapeutics Market

• 27.1. Brazil Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Peptide Therapeutics Market

• 28.1. Middle East Peptide Therapeutics Market Overview
• 28.2. Middle East Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Peptide Therapeutics Market

• 29.1. Africa Peptide Therapeutics Market Overview
• 29.2. Africa Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Peptide Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Peptide Therapeutics Market Competitive Landscape
• 30.2. Peptide Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Jhonson & Jhonson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Peptide Therapeutics Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Sanofi SA
• 31.3. GlaxoSmithKline plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc.
• 31.7. Novo Nordisk AS
• 31.8. Teva Pharmaceuticals Industries Ltd.
• 31.9. Bachem Holding AG
• 31.10. PolyPeptide Laboratories BV
• 31.11. Arcus Biosciences Inc.
• 31.12. Pepscan Therapeutics
• 31.13. Peptech Inc.
• 31.14. Peptide Logic Inc.
• 31.15. SELLAS Life Sciences Group

32. Global Peptide Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Peptide Therapeutics Market

34. Recent Developments In The Peptide Therapeutics Market

35. Peptide Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Peptide Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Peptide Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Peptide Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer